Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: A multicenter study

A. Ferrero, A. Ditto, G. Giorda, A. Gadducci, S. Greggi, A. Daniele, L. Fuso, E. Panuccio, C. Scaffa, F. Raspagliesi, P. Sismondi, N. Biglia

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction Chemotherapy is the standard treatment of recurrent epithelial ovarian cancer (EOC), but its use in nodal relapses is still debated. On the other hand, the role of secondary cytoreductive surgery (SCS) remains controversial. Aim of this study is to evaluate feasibility and outcomes of SCS for the specific setting of recurrent ovarian cancer, exclusively relapsing in lymph nodes. Patients and methods We conducted a retrospective analysis in five Italian Institutions (University of Torino, INT of Milano, CRO of Aviano, University of Pisa and INT of Napoli) from 2000 to 2012. Patients with EOC who underwent secondary surgery for isolated lymph node recurrence (ILNR) were selected. Results Seventy-three patients were identified. At first diagnosis, patients received debulking surgery and platinum-based chemotherapy. The median disease free interval from completion of primary chemotherapy to nodal recurrence was 18 months. Nodal recurrence was para-aortic in 37 patients (50.7%), pelvic in 21 (28.8%), pelvic and para-aortic in 9 (12.3%), pelvic and inguinal in 3 (4.1%) and inguinal in 3 (4.1%). During SCS, in 1 patients nephrectomy was necessary for renal vein injury. No significant postoperative morbidity occurred. Median follow-up is 50 months. After secondary surgery, 32 (43.8%) are alive without disease, 18 (24.6%) are alive with disease and 23 patients (31.5%) are dead of disease. Five-year overall survival from the time of treatment of recurrent disease is 64%. Conclusions Secondary surgery for ILNR of ovarian cancer is feasible, safe, with low morbidity and it is associated with a favorable outcome.

Original languageEnglish
Pages (from-to)891-898
Number of pages8
JournalEuropean Journal of Surgical Oncology
Volume40
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Multicenter Studies
Lymph Nodes
Recurrence
Groin
Drug Therapy
Ovarian Neoplasms
Morbidity
Renal Veins
Ovarian epithelial cancer
Platinum
Nephrectomy
Survival
Wounds and Injuries
Therapeutics

Keywords

  • Epithelial ovarian cancer
  • Isolated lymph node recurrence
  • Secondary cytoreductive surgery

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer : A multicenter study. / Ferrero, A.; Ditto, A.; Giorda, G.; Gadducci, A.; Greggi, S.; Daniele, A.; Fuso, L.; Panuccio, E.; Scaffa, C.; Raspagliesi, F.; Sismondi, P.; Biglia, N.

In: European Journal of Surgical Oncology, Vol. 40, No. 7, 2014, p. 891-898.

Research output: Contribution to journalArticle

Ferrero, A. ; Ditto, A. ; Giorda, G. ; Gadducci, A. ; Greggi, S. ; Daniele, A. ; Fuso, L. ; Panuccio, E. ; Scaffa, C. ; Raspagliesi, F. ; Sismondi, P. ; Biglia, N. / Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer : A multicenter study. In: European Journal of Surgical Oncology. 2014 ; Vol. 40, No. 7. pp. 891-898.
@article{3755cd29f50f4345abc741e0d8e65a4b,
title = "Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: A multicenter study",
abstract = "Introduction Chemotherapy is the standard treatment of recurrent epithelial ovarian cancer (EOC), but its use in nodal relapses is still debated. On the other hand, the role of secondary cytoreductive surgery (SCS) remains controversial. Aim of this study is to evaluate feasibility and outcomes of SCS for the specific setting of recurrent ovarian cancer, exclusively relapsing in lymph nodes. Patients and methods We conducted a retrospective analysis in five Italian Institutions (University of Torino, INT of Milano, CRO of Aviano, University of Pisa and INT of Napoli) from 2000 to 2012. Patients with EOC who underwent secondary surgery for isolated lymph node recurrence (ILNR) were selected. Results Seventy-three patients were identified. At first diagnosis, patients received debulking surgery and platinum-based chemotherapy. The median disease free interval from completion of primary chemotherapy to nodal recurrence was 18 months. Nodal recurrence was para-aortic in 37 patients (50.7{\%}), pelvic in 21 (28.8{\%}), pelvic and para-aortic in 9 (12.3{\%}), pelvic and inguinal in 3 (4.1{\%}) and inguinal in 3 (4.1{\%}). During SCS, in 1 patients nephrectomy was necessary for renal vein injury. No significant postoperative morbidity occurred. Median follow-up is 50 months. After secondary surgery, 32 (43.8{\%}) are alive without disease, 18 (24.6{\%}) are alive with disease and 23 patients (31.5{\%}) are dead of disease. Five-year overall survival from the time of treatment of recurrent disease is 64{\%}. Conclusions Secondary surgery for ILNR of ovarian cancer is feasible, safe, with low morbidity and it is associated with a favorable outcome.",
keywords = "Epithelial ovarian cancer, Isolated lymph node recurrence, Secondary cytoreductive surgery",
author = "A. Ferrero and A. Ditto and G. Giorda and A. Gadducci and S. Greggi and A. Daniele and L. Fuso and E. Panuccio and C. Scaffa and F. Raspagliesi and P. Sismondi and N. Biglia",
year = "2014",
doi = "10.1016/j.ejso.2013.11.026",
language = "English",
volume = "40",
pages = "891--898",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer

T2 - A multicenter study

AU - Ferrero, A.

AU - Ditto, A.

AU - Giorda, G.

AU - Gadducci, A.

AU - Greggi, S.

AU - Daniele, A.

AU - Fuso, L.

AU - Panuccio, E.

AU - Scaffa, C.

AU - Raspagliesi, F.

AU - Sismondi, P.

AU - Biglia, N.

PY - 2014

Y1 - 2014

N2 - Introduction Chemotherapy is the standard treatment of recurrent epithelial ovarian cancer (EOC), but its use in nodal relapses is still debated. On the other hand, the role of secondary cytoreductive surgery (SCS) remains controversial. Aim of this study is to evaluate feasibility and outcomes of SCS for the specific setting of recurrent ovarian cancer, exclusively relapsing in lymph nodes. Patients and methods We conducted a retrospective analysis in five Italian Institutions (University of Torino, INT of Milano, CRO of Aviano, University of Pisa and INT of Napoli) from 2000 to 2012. Patients with EOC who underwent secondary surgery for isolated lymph node recurrence (ILNR) were selected. Results Seventy-three patients were identified. At first diagnosis, patients received debulking surgery and platinum-based chemotherapy. The median disease free interval from completion of primary chemotherapy to nodal recurrence was 18 months. Nodal recurrence was para-aortic in 37 patients (50.7%), pelvic in 21 (28.8%), pelvic and para-aortic in 9 (12.3%), pelvic and inguinal in 3 (4.1%) and inguinal in 3 (4.1%). During SCS, in 1 patients nephrectomy was necessary for renal vein injury. No significant postoperative morbidity occurred. Median follow-up is 50 months. After secondary surgery, 32 (43.8%) are alive without disease, 18 (24.6%) are alive with disease and 23 patients (31.5%) are dead of disease. Five-year overall survival from the time of treatment of recurrent disease is 64%. Conclusions Secondary surgery for ILNR of ovarian cancer is feasible, safe, with low morbidity and it is associated with a favorable outcome.

AB - Introduction Chemotherapy is the standard treatment of recurrent epithelial ovarian cancer (EOC), but its use in nodal relapses is still debated. On the other hand, the role of secondary cytoreductive surgery (SCS) remains controversial. Aim of this study is to evaluate feasibility and outcomes of SCS for the specific setting of recurrent ovarian cancer, exclusively relapsing in lymph nodes. Patients and methods We conducted a retrospective analysis in five Italian Institutions (University of Torino, INT of Milano, CRO of Aviano, University of Pisa and INT of Napoli) from 2000 to 2012. Patients with EOC who underwent secondary surgery for isolated lymph node recurrence (ILNR) were selected. Results Seventy-three patients were identified. At first diagnosis, patients received debulking surgery and platinum-based chemotherapy. The median disease free interval from completion of primary chemotherapy to nodal recurrence was 18 months. Nodal recurrence was para-aortic in 37 patients (50.7%), pelvic in 21 (28.8%), pelvic and para-aortic in 9 (12.3%), pelvic and inguinal in 3 (4.1%) and inguinal in 3 (4.1%). During SCS, in 1 patients nephrectomy was necessary for renal vein injury. No significant postoperative morbidity occurred. Median follow-up is 50 months. After secondary surgery, 32 (43.8%) are alive without disease, 18 (24.6%) are alive with disease and 23 patients (31.5%) are dead of disease. Five-year overall survival from the time of treatment of recurrent disease is 64%. Conclusions Secondary surgery for ILNR of ovarian cancer is feasible, safe, with low morbidity and it is associated with a favorable outcome.

KW - Epithelial ovarian cancer

KW - Isolated lymph node recurrence

KW - Secondary cytoreductive surgery

UR - http://www.scopus.com/inward/record.url?scp=84901481831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901481831&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2013.11.026

DO - 10.1016/j.ejso.2013.11.026

M3 - Article

C2 - 24378007

AN - SCOPUS:84901481831

VL - 40

SP - 891

EP - 898

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 7

ER -